A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Phase 1 Completed 25 enrolled Elicio Therapeutics

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides\]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.

Timeline

Start: 2021-10-04
Primary completion: 2023-01-26
Completion: 2024-09-24

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ELI-002 2P	Vaccine	0.1 mg	Subcutaneous
Subject	ELI-002 2P	Vaccine	0.5 mg	Subcutaneous
Subject	ELI-002 2P	Vaccine	2.5 mg	Subcutaneous
Subject	ELI-002 2P	Vaccine	5 mg	Subcutaneous
Subject	ELI-002 2P	Vaccine	10 mg	Subcutaneous

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Summary

Timeline

Publications

Drugs

Indications